Skip to main content
Figure 2 | Journal of Neuroinflammation

Figure 2

From: Blockade of interleukin-6 signaling inhibits the classic pathway and promotes an alternative pathway of macrophage activation after spinal cord injury in mice

Figure 2

Immunoblot analysis of T helper (Th)1 and Th 2 cytokines after MR16-1 treatment. (A, B) Interferon (IFN)-γ levels were consistently higher in the control groups, and the difference with the MR16-1-treated group was significant up to 7 days post-injury. (C, D) Tumor necrosis factor (TNF)-α levels were enhanced in the control groups, and were significantly different compared with the MR16-1-treated group from 1 to 14 days post-injury. (E, F) Interleukin (IL)-4 levels remained significantly higher in the MR16-1-treated group from 1 to 7 days post-injury compared with the controls. (G, H) IL-13 levels were increased in the MR16-1-treated group, and were significantly different to the control groups between 1 and 4 days post-injury. No difference was found in the cytokine expression between the control groups (saline and Rat IgG). Each graph indicates relative band intensity normalized to that of β-actin. (B, D, F, H) Data are expressed as mean ± SD, n = 3 for each group. *P ≤ 0.05, **P ≤ 0.01 by ANOVA

Back to article page